Australian ADHD Guideline
Recent reporting on ADHD in Australia has sparked debate, particularly around the development of the Australian Evidence-Based Clinical Practice Guideline for ADHD and AADPA’s Prescribing Guides. In response to inaccuracies raised in a recent Four Corners episode, the Australasian ADHD Professionals Association (AADPA) has clarified how these resources were created, funded, and approved. You can read their article here.
The key message is simple: the Australian ADHD Guideline and Prescribing Guides were developed through a rigorous, transparent process and were not shaped by pharmaceutical industry funding. Here is what the public needs to know.
The guideline was independently validated
One of the strongest points in support of the Australian ADHD Guideline is that it was approved by the National Health and Medical Research Council (NHMRC), Australia’s peak health and medical research body.
This matters because NHMRC approval is not a routine box-ticking exercise. It means a guideline has met high standards for methodological quality, transparency and independence. According to NHMRC Chief Executive Officer Professor Steve Wesselingh, it represents “the gold standard of guidelines in Australia”.
For clinicians, patients and families, that approval offers reassurance that the guideline was assessed under strict national standards rather than shaped by opinion or outside influence.
How the Australian ADHD Guideline was developed
The guideline was developed over two years using recognised evidence-based methods that align with NHMRC requirements and international best practice.
AADPA used the GRADE evidence-to-recommendation framework, which is widely used in healthcare guideline development. This approach looks at more than one type of input. It considers:
systematic reviews of available research
multidisciplinary clinical expertise
lived experience perspectives
the balance of benefits and harms
That is important in ADHD care, where not every clinical question has high-certainty trial evidence behind it. In cases where evidence is limited, high-quality guidelines still need a structured and transparent way to make recommendations.
Different types of recommendations serve different purposes
The Australian ADHD Guideline includes several kinds of recommendations, each based on the strength and availability of evidence.
These include:
evidence-based recommendations, informed by systematic reviews
clinical consensus recommendations, used where evidence is limited but guidance is still needed
clinical practice points, which support safe and effective care in areas outside formal evidence reviews
This mix is standard in healthcare guideline development, especially in mental health and neurodevelopmental conditions. It does not weaken the guideline. Instead, it reflects the reality of clinical practice and the need to give clear guidance even where research is still evolving.
AADPA has stressed that consensus-based recommendations are a recognised part of high-quality clinical guidelines, including those accepted by NHMRC and used by international organisations such as NICE in the UK.
Public consultation and expert oversight were built in
The development process also included public consultation. Draft recommendations were released for public comment and revised in response to feedback, in line with NHMRC processes.
The final guideline was endorsed by relevant medical colleges, professional associations, and major consumer organisations involved in its development. That broad support strengthens confidence in the final document and reflects input from both professionals and people with lived experience.
The Prescribing Guides were developed under the same principles of independence, transparency, and evidence-informed decision-making.
What about sponsorship and conflicts of interest?
AADPA has acknowledged that, like many professional associations, it does accept sponsorship from a range of organisations, including pharmaceutical companies, to help cover the cost of its annual conference.
However, it says these sponsors have no role in conference programming, guideline development or educational content. That distinction is important. Event sponsorship is not the same as funding a clinical guideline, and AADPA maintains that its ADHD resources were developed without industry influence.
Conflicts of interest were also formally declared and managed throughout the guideline development process in line with NHMRC requirements. Where relevant conflicts existed, members were excluded from voting on related recommendations.
This sort of conflict management is a required part of NHMRC approval and helps protect the integrity of the final recommendations.
Why this clarification matters
ADHD diagnosis, treatment, and support remain areas of strong public interest. When concerns are raised about independence or evidence standards, they can affect public trust and create uncertainty for people seeking care.
AADPA’s clarification aims to reassure clinicians, consumers and the broader community that the Australian ADHD Guideline and Prescribing Guides were developed through a robust and transparent process. The organisation’s position is that these resources remain an important foundation for consistent, evidence-informed ADHD care across Australia.
At a time when public discussion around ADHD is growing, accuracy matters. Clear information about how guidelines are developed, who funds them, and how conflicts are managed is essential for informed debate and good healthcare.
Summary
The Australian ADHD Guideline was approved by the NHMRC, built using recognised evidence-based methods and funded by the Australian Government, not pharmaceutical companies. The Prescribing Guides were developed under the same principles of transparency and independence.
If you want a deeper understanding of how the guideline was developed, funded, and reviewed, it is worth reading AADPA’s full clarification and FAQ materials on the topic.